

## **AIDS 2018 Track B abstract submission categories**

Track B - Clinical Research		
	se of HIV disease	
B1	Acute and early infection	
B2	Impact of co-factors (e.g. viral clade, tropism, genetic factors) on disease	
DO	progression	
B3	Long-term non-progressors and elite controllers	
B4	Morbidity, mortality and life expectancy in clinical research	
B5 Dies	HIV-2	
B6	nostic and monitoring tools  HIV testing and retesting (e.g. point of care diagnostics)	
B7	CD4 measurement (e.g. point of care diagnostics)	
B8	Viral load measurement (e.g. point of care diagnostics)	
B9	Measuring ART adherence (drug levels, dried blood spots, hair sampling)	
B10	Drug resistance testing	
B11	Diagnostics of co-infections and comorbidities	
B12	Biomarkers for the prediction of morbidity and mortality	
	nfections (including opportunistic infections)	
B13	Opportunistic infections (excluding TB)	
B14	Tuberculosis	
B15		
	Viral hepatitis B and D	
	Viral hepatitis C	
B18		
B19	STI's including HPV	
	orbidities and complications (including those related to ART)	
B20	Neurologic disorders	
B21	Depression and other psychiatric manifestations	
B22	Malignancies (AIDS and non-AIDS)	
B23	Cardio-vascular disease	
B24	Bone disease	
B25	Renal disease	
B26	Metabolic, lipid and endocrine complications, including obesity and lipodystrophy	
B27	Hepatic complications (e.g. NASH)	
B28	Ageing with HIV (including polypharmacy and frailty)	
B29	Immune reconstitution disorders / immune reconstitution inflammatory syndrome (IRIS)	
B30	Other non-communicable diseases	
B31	Other ART complications and adverse reactions	
	etroviral therapies in adults	
B32	ART in acute infection	
B33	ART in first- and second-line therapies	
B34	ART in highly treatment-experienced persons	
B35	Regimen simplification and switch studies	
B36	Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug	
	monitoring	

B37	Drug interactions	
B38	Antiretroviral drug resistance	
B39	Long-acting agents and other drug delivery systems	
B40	Adherence	
B41	Ethical issues in clinical trials and treatment strategies	
Other strategies and therapies		
B42	Therapeutic vaccine trials	
B43	Immune-based therapy trials	
B44	Cure interventions	
B45	Complementary and traditional medicines	
B46	Nutrition	
Clinical issues specific to gender		
B47	Sex-specific issues of ART efficacy, adverse reactions and complications	
B48	Pregnancy (clinical management issues and pharmacokinetics)	
B49	Contraception	
B50	Menopause	
Clinical issues specific to paediatric and adolescent HIV		
B51	Diagnosis of HIV disease in paediatric and adolescent populations	
B52	Pharmacokinetics/pharmacodynamics/pharmacogenomics and therapeutic drug	
	monitoring in paediatric and adolescent populations	
B53	Drug formulations for infants and children	
B54	Clinical trials in paediatric and adolescent populations	
B55	ARV management strategies in paediatric and adolescent populations	
B56	Cure strategies in paediatric and adolescent populations	
B57	Adherence in paediatric and adolescent populations	
B58	Opportunistic infections in paediatric and adolescent populations	
B59	HIV complications and comorbidities in paediatric and adolescent populations	
B60	HIV-associated co-infections and malignancies in paediatric and adolescent	
	populations	
B61	Behavioural health outcomes in paediatric and adolescent populations	
B62	Mental health and neuro-cognition in paediatric and adolescent populations	
B63	HIV-exposed uninfected children	
B64	Transition of adolescents into adult care	
Clinical issues specific to key populations & vulnerable populations		
B65	Clinical issues in men who have sex with men	
B66	Clinical issues in people who use drugs	
B67	Clinical issues in sex workers	
B68	Clinical issues in transgender and non-binary populations	
B69	Clinical issues in migrants	
B70	Clinical issues in other vulnerable populations	
B71	Ethical considerations related to clinical research with key populations and other	
	vulnerable populations	